By Michele Maatouk
Date: Thursday 13 Mar 2025
(Sharecast News) - Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.
Under the terms of the agreement, Endo shareholders will receive $80m in cash and will own 49.9% of the combined company on a pro forma basis, while Mallinckrodt shareholders will...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news